Application of the ‘5-2-1’ screening criteria in advanced Parkinson’s disease: interim analysis of DUOGLOBE-Reference-Cited by-同舟云学术

Application of the ‘5-2-1’ screening criteria in advanced Parkinson’s disease: interim analysis of DUOGLOBE

Published:2020-10 Issue:5 Volume:10 Page:309-323
ISSN:1758-2024
Container-title:Neurodegenerative Disease Management
language:en
Short-container-title:Neurodegenerative Disease Management

Author:

Aldred Jason¹^ORCID,Anca-Herschkovitsch Marieta²,Antonini Angelo³,Bajenaru Ovidiu⁴,Bergmann Lars⁵,Bourgeois Paul⁶,Cubo Esther⁷,Davis Thomas L⁸,Iansek Robert⁹,Kovács Norbert¹⁰,Kukreja Pavnit⁵,Onuk Koray⁵,Pontieri Francesco E¹¹,Robieson Weining⁵,Siddiqui Mustafa S¹²,Simu Mihaela¹³,Standaert David G¹⁴,Chaudhuri K Ray¹⁵

Affiliation:

1. Selkirk Neurology & Inland Northwest Research, Spokane, 610 S Sherman St #201 & 208, Spokane, WA 99202, USA

2. Department of Neurology, Edith Wolfson Medical Center Affiliated to Tel Aviv University, 62 Ha-Lokhamim St, Holon, Israel

3. Department of Neuroscience, Padua University, 5 - 35128 Padova, Padua, Veneto, Italy

4. Department of Neurology, University of Medicine & Pharmacy “Carol Davila”, Bulevardul Eroii Sanitari 8, Bucharest, Romania

5. AbbVie, Inc., 1 Waukegan Rd, North Chicago, IL 60064, USA

6. Department of Neurology AZ Groeninge, President Kennedylaan 4, Kortrijk, Belgium

7. Neurology Department, Hospital Universitario Burgos, Av. Islas Baleares, 3, Burgos, Spain

8. Department of Neurology, Vanderbilt University Medical Center, 1211 Medical Center Dr, Nashville, TN 37232, USA

9. Kingston Centre, Monash Health, 400 Warrigal Rd, Melbourne, Victoria, Australia

10. Department of Neurology, University of Pecs, 48-as tér 1, Pecs, Hungary

11. Department of Neurological Sciences, Sapienza University of Rome, Piazzale Aldo Moro, 5, Rome, Italy

12. Department of Neurology, Wake Forest School of Medicine, 475 Vine St, Winston Salem, NC 27101, USA

13. Department of Neurology, Victor Babes University of Medicine & Pharmacy, Piaţa Eftimie Murgu 2, Timisoara, Romania

14. Department of Neurology, University of Alabama at Birmingham, 1720 University Blvd, Birmingham, AL 35294, USA

15. Parkinson Foundation International Centre of Excellence, King’s College & King’s College Hospital, Denmark Hill, London, UK

Abstract

Aim: A Delphi expert consensus panel proposed that fulfilling ≥1 of the ‘5-2-1 criteria’ (≥five-times daily oral levodopa use, ≥two daily hours with ‘Off’ symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson’s disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD – a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE) – is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa–carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment. Clinical Trial Registration: NCT02611713 ( ClinicalTrials.gov )

Publisher

Future Medicine Ltd

Subject

Neurology (clinical)

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nmt-2020-0021

Reference37 articles.

1. Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine

2. Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinsonʼs Disease

3. Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features

4. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach

5. Personalized medicine in Parkinson's disease: Time to be precise

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Are 5-2-1 Delphi criteria and MANAGE-PD useful screening tools for general neurologists for qualification to device-aided therapies in advanced Parkinson’s Disease?;Neurologia i Neurochirurgia Polska;2024-08-28

2. Grasping the big picture: impact analysis of screening tools for timely referral for device-aided therapies;Journal of Neural Transmission;2024-07-15

3. Utilization of MANAGE-PD Tool in a Real-World Setting in Germany: A Cross-Sectional Study;Brain Sciences;2024-06-24

4. Levodopa-based device-aided therapies for the treatment of advanced Parkinson’s disease: a social return on investment analysis;Frontiers in Public Health;2024-06-06

5. Comment on “Does the 5-2-1 criteria identify patients with advanced Parkinson’s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries”;BMC Neurology;2024-06-05